No connection

Search Results

HRTX

BEARISH
$0.85 Live
Heron Therapeutics, Inc. · NASDAQ
Target $4.33 (+408.0%)
$0.74 52W Range $2.61
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 11, 2026
Market cap
$160.82M
P/E
N/A
ROE
N/A
Profit margin
-13.0%
Debt/Equity
9.81
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.

Key Strengths

Strong Gross Margin of 72.64%
Healthy liquidity with a Current Ratio of 2.48
Operating margin is near break-even (0.09%)
Low Price-to-Sales ratio (1.04)
Strong analyst target price relative to current market price

Key Risks

Extreme leverage with Debt/Equity at 9.81
Severe long-term value destruction (5Y Change: -94.8%)
Stagnant revenue growth (-0.50% YoY)
High Price-to-Book ratio (12.01) indicating overvaluation relative to assets
Consistent history of negative profit margins (-13.04%)
AI Fair Value Estimate
Based on comprehensive analysis
$1.15
+34.8% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
25
Weak
Value
40
Future
45
Past
10
Health
30
Dividend
0
AI Verdict
Speculative / High Risk
Key drivers: Extreme Debt/Equity ratio, Severe price decay, Disconnect between analyst targets and fundamentals
Confidence
90%
Value
40/100

Trades cheap on sales but expensive on book value; Forward P/E suggests aggressive earnings expectations.

Positives
  • Low P/S ratio (1.04)
  • Very low Forward P/E (1.67)
Watchpoints
  • High P/B ratio (12.01)
  • No Graham Number available due to lack of earnings
Future
45/100

Growth is currently stagnant; future success depends entirely on earnings inflection.

Positives
  • Strong analyst conviction
  • Improving EPS trajectory in recent quarters
Watchpoints
  • Negative YoY revenue growth
  • Negative profit margins
Past
10/100

Historical price performance is catastrophic.

Positives
  • Recent Q/Q EPS growth (+80%)
Watchpoints
  • 5Y return of -94.8%
  • 1Y return of -53.1%
Health
30/100

Liquidity is sufficient for the short term, but solvency is a major concern due to leverage.

Positives
  • Piotroski F-Score of 4/9 (Stable)
  • Current Ratio 2.48
Watchpoints
  • Debt/Equity ratio of 9.81 is critical
  • Negative ROA
Dividend
0/100

Non-dividend paying biotech.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.85
Analyst Target
$4.33
Upside/Downside
+408.0%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for HRTX and closest competitors.

Updated 2026-04-10
HRT
Heron Therapeutics, Inc.
Primary
5Y
-94.8%
3Y
-68.8%
1Y
-53.1%
6M
-33.4%
1M
-12.1%
1W
+6.6%
ACH
Accendra Health, Inc.
Peer
5Y
-92.8%
3Y
-89.2%
1Y
-85.8%
6M
-73.2%
1M
-22.1%
1W
-16.3%
DER
Journey Medical Corporation
Peer
5Y
-50.0%
3Y
+251.1%
1Y
-28.9%
6M
-34.4%
1M
-38.3%
1W
+5.5%
APY
Apyx Medical Corporation
Peer
5Y
-68.5%
3Y
+28.3%
1Y
+249.0%
6M
+72.9%
1M
-7.4%
1W
+16.4%
AGE
Agenus Inc.
Peer
5Y
-93.5%
3Y
-88.0%
1Y
+124.2%
6M
-10.7%
1M
+36.6%
1W
+18.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
1.67
PEG Ratio
N/A
P/B Ratio
12.01
P/S Ratio
1.04
EV/Revenue
1.65
EV/EBITDA
-1142.32
Market Cap
$160.82M

Profitability

Profit margins and return metrics

Profit Margin -13.04%
Operating Margin 0.09%
Gross Margin 72.64%
ROE N/A
ROA -0.65%

Growth

Revenue and earnings growth rates

Revenue Growth -0.5%
Earnings Growth N/A
Q/Q Revenue Growth -0.47%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
9.81
High debt
Current Ratio
2.48
Strong
Quick Ratio
1.42
Good
Cash/Share
$0.25

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
72.6%
Op. Margin
0.1%
Net Margin
-7.3%
Total Assets
$0.3B
Liabilities
$0.2B
Equity
$0.0B
Debt/Equity
16.85x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-05
$N/A
2026-02-26
$-0.02
+33.3% surprise
2025-11-04
$-0.1
-566.7% surprise
2025-08-08
$-0.02
-100.0% surprise

Healthcare Sector Comparison

Comparing HRTX against 226 companies in the Healthcare sector (19 bullish, 76 neutral, 131 bearish)
Profit Margin
-13.04%
This Stock
vs
-18.65%
Sector Avg
-30.1% (Weaker)
Debt to Equity
9.81
This Stock
vs
4.61
Sector Avg
+113.0% (Higher)
Revenue Growth
-0.5%
This Stock
vs
97.21%
Sector Avg
-100.5% (Slower)
Current Ratio
2.48
This Stock
vs
3.51
Sector Avg
-29.4% (Weaker)

Similar Companies

Peer comparison within the same industry

HRTX Heron Therapeutics, Inc.
BEARISH
Mkt Cap
$161M
P/E
-
ROE
-%
Price
$0.85
ACH Accendra Health, Inc.
BEARISH
Mkt Cap
$163M
P/E
-
ROE
-196.4%
Price
$2.11
 Compare with HRTX
DERM Journey...
BEARISH
Mkt Cap
$165M
P/E
-
ROE
-44.0%
Price
$4.95
 Compare with HRTX
APYX Apyx Medical...
BULLISH
Mkt Cap
$149M
P/E
-
ROE
-76.1%
Price
$3.63
 Compare with HRTX
AGEN Agenus Inc.
BEARISH
Mkt Cap
$144M
P/E
-
ROE
-%
Price
$3.99
 Compare with HRTX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

COLLARD CRAIG ALEXANDER
Chief Executive Officer
Stock Award
2026-04-02
62,500 shares
CUSACK THOMAS J
Director
Stock Award
2026-01-30
53,960 shares
DUARTE IRA
Chief Financial Officer
Stock Award
2026-01-30
11,695 shares
KASETA MICHAEL
Director
Stock Award
2026-01-30
53,960 shares
DISSANAIKE SHARMILA
Director
Stock Award
2026-01-30
53,960 shares
MORGAN ADAM
Director
Stock Award
2026-01-30
53,960 shares
CHRISTIAN WAAGE
Director
Stock Award
2026-01-30
53,960 shares
FORBES WILLIAM P
Officer
Stock Award
2026-01-30
11,695 shares
COLLARD CRAIG ALEXANDER
Chief Executive Officer
Stock Award
2026-01-30
34,789 shares
JOHNSON CRAIG A
Director
Stock Award
2026-01-30
53,960 shares
DUARTE IRA
Chief Financial Officer
Stock Award
2026-01-16
3,875 shares
FORBES WILLIAM P
Officer
Stock Award
2026-01-16
3,875 shares
COLLARD CRAIG ALEXANDER
Chief Executive Officer
Stock Award
2026-01-16
13,797 shares
CUSACK THOMAS J
Director
Stock Award
2025-11-07
37,879 shares
DUARTE IRA
Chief Financial Officer
Stock Award
2025-10-31
11,694 shares
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
3 analysts
HC Wainwright & Co.
2026-01-09
reit
Buy Buy

Past News Coverage

Recent headlines mentioning HRTX from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile